PTHS - Chromocell Therapeutics Corp

23.12
0.710   3.071%

Share volume: 2,622
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.17%

PREVIOUS CLOSE
CHG
CHG%
$22.41
0.71
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
44%
Profitability 60%
Dept financing 43%
Liquidity 35%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.42%
1 Month
4.71%
3 Months
-14.78%
6 Months
-28.11%
1 Year
1,184.44%
2 Year
936.77%
Key data
Stock price
$23.12
P/E Ratio 
0.00
DAY RANGE
$23.11 - $23.12
EPS 
N/A
52 WEEK RANGE
$0.90 - $54.29
52 WEEK CHANGE
$1,184.44
MARKET CAP 
85.180 M
YIELD 
N/A
SHARES OUTSTANDING 
3.062 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$6,378
AVERAGE 30 VOLUME 
$5,032
Company detail
CEO: Francis Knuettel II
Region: US
Website: chromocell.com
Employees: 0
IPO year: 2024
Issue type:
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Chromocell Therapeutics Corporation was incorporated in Delaware on March 19, 2021. Our principal executive offices are located at 4400 Route 9 South, Suite 1000, Freehold, NJ.

Recent news